XML 60 R46.htm IDEA: XBRL DOCUMENT v3.25.2
Acquisitions - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 5 Months Ended 6 Months Ended
Mar. 24, 2025
Mar. 23, 2025
Jan. 16, 2025
Jan. 15, 2025
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2025
Dec. 31, 2024
Disclosure of detailed information about business combination [line items]                      
Goodwill         $ 9,181   $ 9,181 $ 9,181     $ 8,946
Cash paid for the acquisition               $ 568 $ 0    
Forecast | LENSAR, Inc.                      
Disclosure of detailed information about business combination [line items]                      
Total consideration (up to)                   $ 430  
Aurion Biotech, Inc.                      
Disclosure of detailed information about business combination [line items]                      
Ownership percentage in subsidiary 99.00%                    
Ownership percentage in subsidiary on a fully diluted basis 85.00%       91.20%   91.20% 91.20%      
Ownership percentage in subsidiary held by non-controlling interests on a fully diluted basis 15.00%       8.80%   8.80% 8.80%      
Aurion Biotech, Inc.                      
Disclosure of detailed information about business combination [line items]                      
Investment ownership percentage   40.30%                  
Cylite Pty Ltd.                      
Disclosure of detailed information about business combination [line items]                      
Investment ownership percentage       8.80%              
Ownership percentage in subsidiary     100.00%                
Aurion Biotech, Inc.                      
Disclosure of detailed information about business combination [line items]                      
Percentage of outstanding shares acquired 58.70%                    
Total acquisition date fair value of consideration $ 486                    
Previously-held commercialization rights in intangible assets 36                    
Cash paid at closing 522       $ 522   $ 522 $ 522      
Goodwill 140       140   140 140      
Cash paid for the acquisition 496                    
Previously-held investment in associated company 334       334   334 334      
Equity interest remeasurement fair value gain           $ 136          
Direct acquisition cost 2                    
Reduction in net income from acquired business         17            
Non-controlling interests $ 27       27   27 $ 27      
Aurion Biotech, Inc. | Current marketed products                      
Disclosure of detailed information about business combination [line items]                      
Measurement period adjustments, Intangible assets         5            
Aurion Biotech, Inc. | Acquired IPR&D                      
Disclosure of detailed information about business combination [line items]                      
Measurement period adjustments, Intangible assets         $ (5)            
Cylite Pty Ltd.                      
Disclosure of detailed information about business combination [line items]                      
Percentage of outstanding shares acquired     91.20%                
Total acquisition date fair value of consideration     $ 123                
Cash paid at closing     78                
Goodwill     90                
Cash paid for the acquisition     72                
Previously-held investment in associated company     14                
Equity interest remeasurement fair value gain           $ 6          
Direct acquisition cost     1                
Reduction in net income from acquired business             $ 8        
Contingent consideration, maximum     $ 10